Valneva SE (NASDAQ:VALN) Short Interest Update

Valneva SE (NASDAQ:VALN) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 30,600 shares, an increase of 111.0% from the November 15th total of 14,500 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 23,500 shares, the days-to-cover ratio is currently 1.3 days.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price target on Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, October 11th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC boosted its position in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Price Performance

Shares of VALN stock remained flat at $3.93 during mid-day trading on Friday. 8,124 shares of the stock traded hands, compared to its average volume of 13,747. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The company has a 50-day simple moving average of $5.03 and a 200 day simple moving average of $6.49. Valneva has a 1 year low of $3.82 and a 1 year high of $10.93. The stock has a market capitalization of $319.30 million, a P/E ratio of -30.23 and a beta of 1.98.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.